

AVITA SUCCESSFULLY COMPLETES SPP

Australia, 16 April 2015 — Avita Medical Ltd. (ASX: [AVH](#)), (OTCQX: [AVMXY](#)), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the completion of the Share Purchase Plan ("SPP"). The SPP raised \$1,135,500 via the issue of 18,314,508 shares at \$0.062 per share.

The board and management of Avita Medical are appreciative of the strong support received from shareholders for the Company's SPP with the funds raised to help drive the continued development of the Regenerative product platform while driving the commercial stage pipeline.

Shares issued under the SPP will rank equally with existing shares and were allotted on 15 April 2015 with Holding statements to be despatched to participants on, or around, 16 April 2015.

ABOUT AVITA MEDICAL LIMITED

Avita Medical (<http://www.avitamedical.com/>) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray-On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

#

FOR FURTHER INFORMATION:

Avita Medical Ltd.
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
Email: trooney@avitamedical.com

Avita Medical Ltd.
Lou Panaccio
Chairman
Phone: +61 (0) 8 9474 7738
Email: lpnaccio@avitamedical.com